Management of coagulopathy in the setting of acute neurosurgical disease and injury

Neurocritical Care

Volumn 5, Issue 2, 2006, Pages 141-152

  Mathews, Marlon ^a   Newman, Richard ^b   Chappell, E Thomas ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALTEPLASE; ANGELICA SINENSIS EXTRACT; ANTICOAGULANT AGENT; APROTININ; ARGATROBAN; CLOPIDOGREL; DIPYRIDAMOLE; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; GARLIC EXTRACT; GINKGO BILOBA EXTRACT; GINSENG EXTRACT; HEPARIN; HIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; LYSINE DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; PROTHROMBIN COMPLEX; RED CLOVER EXTRACT; TANACETUM PARTHENIUM EXTRACT; TICLOPIDINE; TIROFIBAN; TISSUE PLASMINOGEN ACTIVATOR; UNINDEXED DRUG; VITAMIN K GROUP; WARFARIN;

ACUTE HEART INFARCTION; ALZHEIMER DISEASE; ANAPHYLAXIS; AWARENESS; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; BLOOD COMPONENT THERAPY; BRAIN HEMORRHAGE; CEREBROVASCULAR DISEASE; CLAUDICATION; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG HYPERSENSITIVITY; ERYTHROCYTE; HEART INFARCTION; HEMOSTASIS; HUMAN; LUNG EMBOLISM; MORBIDITY; MORTALITY; MULTIINFARCT DEMENTIA; PATIENT CARE; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; REVIEW; RISK; SPINAL HEMATOMA; STROKE; SURGEON; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOGENICITY; TINNITUS; VENOUS THROMBOEMBOLISM; VIRAL CONTAMINATION;

EID: 33750929811     PISSN: 15416933     EISSN: None     Source Type: Journal    
DOI: 10.1385/NCC:5:2:141     Document Type: Review

References (93)

1. Davie EW, Ratnof OD. Waterfall sequence for intrinsic blood clotting. Science 1964;145:1310-1312.
2. Heesen M, Winking M, Kemkes-Matthes B, et al. What the neurosurgeon needs to know about the coagulation system. Surg Neurol 1997;47:32-34.
3. Mannucci PM, Bettega D, Cattaneo M. Patterns of development of tachyphylaxis in patients with hemophilia and vWD after repeated doses of DDAVP. Br J Haematol 1992;82:87-93.
4. Hinojosa AQ, Gulati M, Singh V, Lawton MT. Spontaneous intracerebral hemorrhage due to coagulation disorders. Neurosurg Focus 2003;15(4):E3.
5. Aitken MG. Recombinant factor VIIa. Emerg Med Australas 2004;16:446-455.
6. Uprichard J, Perry DJ. Factor X deficiency. Blood Rev 2002;16(2):97-110.
7. Hoffman M. Remodeling the blood coagluation cascade. J Thromb Thrombolysis 2003;16(1-2):17-20.
8. Duke WW. The relation of blood platelets to hemorrhagic disease. JAMA 1910;60:1185-1192.
9. Hellem AJ, Borchgrevink CF, Ames SB. The role of red cells in hemostasis: the relation between the hematocrit, bleeding time and platelet adhesivieness. Br J Haematol 1961;7:42-50.
10. Livio M, Gotti E, Marchesi D, Mecca G, Remuzzi G, de Gaetano G. Uraemic bleeding: role of anaemia and beneficial effect of red cell transfusions. Lancet 1982;2(8306):1013-1015.
11. Fernandez F, Goudable C, Sie P, et al. Low hematocrit and prolonged bleeding time in uraemic patients: effect of red cell transfusions. Br J Haematol 1985;59:139-148.
12. Valeri CR, Cassidy G, Pivacek LE, et al. Anemia-induced increase in the bleeding time: implications for treatment of nonsurgical blood loss. Transfusion 2001;41:977-983.
13. Kundu SK, Heilmann EJ, Sio R, et al. Characterization of an in vitro platelet function analyzer, PFA-100™. Clin Appl Thromb Hemost 1996;2:241-249.
14. Escolar G, Cases A, Vinas M, et al. Evaluation of acquired platelet dysfunctions in uremic and cirrhotic patients using the platelet function analyzer (PFA-100™): influence of hematocrit elevation. Haematologica 1999;84:614-619.
15. Moia M, Mannucci PM, Vizzotto L, Casati S, Cattaneo M, Ponticelli C. Improvement in the haemostatic defect of uraemia after treatment with recombinant human erythropoietin. Lancet 1987;8570:1227-1229.
16. Turitto VT, Baumgartner HR. Platelet interaction with subendothelium in a perfusion system: physical role of red blood cells. Microvasc Res 1975;9:335-344.
17. Koh MB, Hunt BJ. The management of perioperative bleeding. Blood Rev 2003;17:179-185.
18. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971;231:232-235.
19. Steering committee for the Physician's Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health study. N Eng J Med 1989;321:129-135.
20. CAPRIE steering committee. A randomized, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-1339.
21. Roberts HR, Monroe DM, Escobar MA. Current concepts of hemostasis: implications for therapy. Anesthesiology 2004;100:711-730.
22. Saloheimo P, Ahonen M, Juvela S, Pyhtinen J, Savolainen ER, Hillbom M. Regular aspirin-use preceding the onset of primary intracerebral hemorrhage is an independent predictor for death. Stroke 2006;37(1):129-133. Epub 2005 Dec 1.
23. Toyoda K, Okada Y, Minematsu K, et al. Antiplatelet therapy contributes to acute deterioration of intracerebral hemorrhage. Neurology 2005;65(7):1000-1004.
24. Kase CS, Robinson RK, Stein RW, et al. Anticoagulant related cerebral hemorrhage. Neurology 1985;35(7):943-948.
25. Ramstrom G, Sindet-Pedersen S, Hall G, Blomback M, Alander U. Prevention of postsurgical bleeding in oral surgery using tranexamic acid without dose modification of oral anticoagulants. J Oral Maxillofac Surg 1993;51:1211-1216.
26. Rai J. Adverse interactions between low-dose aspirin/warfarin and garlic/ginseng/Ginkgo biloba. Indian Heart J 2004;56(2):176.
27. Sierpina VS, Wollschlaeger B, Blumenthal M. Ginkgo biloba. Am Fam Physician 2003;68(5):923-926. Review.
28. Benjamin J, Muir T, Briggs K, Pentland B. A case of cerebral haemorrhage -can Ginkgo biloba be implicated? Postgrad Med J 2001;77(904):112-113.
29. Purroy Garcia F, Molina C, Alvarez Sabin J. Spontaneous cerebellar haemorrhage associated with Ginkgo biloba ingestion. Med Clin (Barc) 2002;119(15):596-597.
30. Rowin J, Lewis SL. Spontaneous bilateral subdural haematomas associated with chronic Ginkgo biloba ingestion. Neurology 1996;46:1775-1776.
31. Bent S, Goldberg H, Padula A, Avins AL. Spontaneous bleeding associated with ginkgo biloba: a case report and systematic review of the literature. J Gen Intern Med 2005;20(7):657-661.
32. Jayasekera N, Moghal A, Kashif F, Karalliedde L. Herbal medicines and postoperative haemorrhage. Anaesthesia 2005;60(7):725-726.
33. Schneider C, Bord C, Misse P, Arnaud B, Schmitt-Bernard CF. Spontaneous hyphema caused by Ginkgo biloba extract. J Fr Ophtalmol 2002;25(7):731-732.
34. Abebe W. Herbal medication: potential for adverse interactions with analgesic drugs. J Clin Pharm Ther 2002;27(6):391-401. Review.
35. Hodges PJ, Kam PC. The peri-operative implications of herbal medicines. Anaesthesia 2002;57(9):889-899.
36. Clark MA, Paradis NA. Spinal epidural hematoma complicating thrombolytic therapy with tissue plasminogen activator-a case report. J Emerg Med 2002;23(3):247-251.
37. Mahaffey KW, Granger CB, Sloan MA, et al. Neurosurgical evacuation of intracranial hemorrhage after thrombolytic therapy for acute myocardial infarction: experience from the GUSTO-I trial. Global utilization of streptokinase and tissue-plasminogen activator (tPA) for occluded coronary arteries. Am Heart J 1999;138(3 Pt 1):493-499.
38. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-1587.
39. Graham GD. Tissue plasminogen activator for acute ischemic stroke in clinical practice: a meta-analysis of safety data. Stroke 2003;34:2847-2850.
40. Rollins G. Combined stroke trial data confirms that early treatment with thrombolytics improves outcomes. Rep Med Guidel Outcomes Res 2004;15:8-9.
41. Rogers LR. Cerebro vascular complications in cancer patients. Neurol Clin 1991;9:889-899.
42. Graus F, Rogers LR, Posner JB. Cerebro vascular complications in patients with cancer. Medicine (Baltimore) 1985;64:16-35.
43. Goodnight SH Jr. Bleeding and intravascular clotting in malignancy: a review. Ann NY Acad Sci 1974;230:271-288.
44. Gralnick HR, Abrell E. Studies of the procoagulant fibrinolytic activity of promyelocytes in acute promyelocytic leukemis. Br J Hematol 1973;24:89-99.
45. Lukas R. Disseminated intravascular coagulation. Surg Neurol 1995;44(2):184.
46. Brothers TE, Wakefield TW, McLaren ID, Bockenstedt P, Greenfield LJ. Coagulation status during aortic aneurysm surgery: comparison of thromboelastography with standard tests. J Invest Surg 1993;6:527-534.
47. Gibbs NM, Crawford GP, Michalopoulos N. Post operative changes in coagulant and anti-coagulant factors following abdominal aortic aneurysm surgery. J Cardiothorac Vasc Anesth 1992;6:680-685.
48. Seyfer AE, Seaber AV, Dombrose FA, Urbaniak JR. Coagulation changes in elective surgery and trauma. Ann Surg 1981;193:210-213.
49. Abrahams JM, Torchia MB, McGarvey M, Putt M, Baranov D, Sinson GP. Perioperative assessment of coagulability in neurosurgical patients using thromboelastography. Surg Neurol 2002;58:5-12.
50. Levi MM, Vink R, de Jonge E. Management of bleeding disorders by prohemostatic therapy. Int J Hematol 2002;76(Suppl 2):139-144.
51. de Jonge E, Levi M. Effects of different plasma substitutes on blood coagulation: a comparative review. Crit Care Med 2001;29:1261-1267.
52. Genecov DG, Por YC, Barcelo CR, Salyer KE, Mulne AF, Morad AB. Preoperative screening for coagulopathy using prothrombin time and partial thromboplastin time in patients requiring primary cranial vault remodeling. Plast Reconstr Surg 2005;116(2):389-394.
53. Lee WS, Chong LA, Begum S, Abdullah WA, Koh MT, Lim EJ. Factor V inhibitor in neonatal intracranial hemorrhage secondary to severe congenital factor V deficiency. J Pediatr Hematol Oncol 2001;23(4):244-246.
54. Huang WY, Kruskall MS, Bauer KA, Uhl L, Shaz BH. The use of recombinant factor VII in three patients with central nervous system hemorrhages associated with factor VII deficiency. Transfusion 2004;44:1560-1566.
55. Citak A, Ucsel R, Karabocuoglu M, Unuvar A, Uzel N. A rare case of intracranial hemorrhage: factor X deficiency. Pediatr Emerg Care 2001;17(5):349-350.
56. Ermis B, Ors R, Tastekin A, Orhan F. Severe congenital factor X deficiency with intracranial bleeding in two siblings. Brain Dev 2004;26(2):137-138.
57. Fujimoto Y, Aguiar PH, Carneiro JD, et al. Spontaneous epidural hematoma following a shunt in an infant with congenital factor X deficiency. Neurosurg Rev 1999;22:226-229.
58. Gerlach R, Tolle F, Raabe A, Zimmermann M, Siegemund A, Seifert V. Increased risk for postoperative hemorrhage after intracranial surgery in patients with decreased F XIII activity. Stroke 2002;33(6):1618-1623.
59. Pernod G, Barro C, Arnutti B, et al. Case report: surgery in severe factor XIII deficiency: report of a case of epilepsy neurosurgery and review. Haemophilia 2003;9:121-124.
60. Watson HG, Baglin T, Laidlaw SL, Makris M, Preston FE. A comparison of the efficacy and rate of response to oral and intravenous vitamin K in reversal of over-anticoagulation with warfarin. Br J Haematol 2001;115:145-149.
61. Lin Y, Foltz L. Guidelines for platelet transfusion, British Columbia transfusion medicine advisory group. November 2004.
62. Practice Guidelines for blood component therapy: a report by the American Society of Anesthesiologists Task Force on Blood Component Therapy. Anesthesiology 1996;84(3):732-747.
63. de Andrade JR, Jove M. Baseline hemoglobin as a predictor of risk of transfusion and response to epoetin alfa in orthopedic surgery patients. Am J Orthoped 1996;25:544-552.
64. Faris PM, Ritter MA. The effects of recombinant human erythropoietin on perioperative transfusion requirements in patients having a major orthopedic operation. J Bone Joint Surg 1996;78A:62-72.
65. Goldberg MA, McCutchen JW. A safety and efficacy camparison study of two dosing regimens of epoetin alfa in patients undergoing major orthopedic surgery. Am J Orthoped 1996;25:544-552.
66. Turitto VT, Weiss HJ. Red blood cells: their dual role in thrombus formation. Science 1980;207:541-543.
67. Levy JH. Hemostatic agents. Transfusion 2004;44 (Suppl):58S-62S.
68. Segal H, Hunt BJ. Aprotinin: pharmacological reduction of perioperative bleeding. Lancet 2000;355:1289-1290.
69. Royston D, Bidstrup BP, Taylor KM, Sapsford RN. Effects of aprotonin on need for blood transfusion after repeat open heart surgery. Lancet 1987;8571:1289-1291.
70. Palmer JD, Francis JL, Pickard JD, Iannotti F. The efficacy and safety of aprotinin for hemostasis during intracranial surgery. J Neurosurg 2003;98(6):1208-1216.
71. Hanley JP. Review: warfarin reversal. J Clin Path 2004;57:1132-1139.
72. Mannucci PM. Review article: desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood 1997;90(7):2515-2519.
73. Weinstein M, Ware JA, Troll J, Salzman E. Changes in vWF during cardiac surgery: effect of desmopressin acetate. Blood 1988;71:1648-1655.
74. Sakariassen KS, Cattaneo M, vd Berg A, Ruggeri ZM, Mannucci PM, Sixma JJ. DDAVP enhances platelet adherence and platelet aggregate growth on human artery subendothelium. Blood 1984;64:229-236.
75. Di Michele DM, Hathaway WE. Use of DDAVP in inherited and acquired platelet dysfunction. Am J Hematol 1990;33:39.
76. Takeuchi M, Nagura H, Kaneda T. DDAVP and epinephrine induce changes in the localization of vWF antigen in endothelial cells of human oral mucosa. Task Force on Blood Component Therapy. Anesthesiology 1996;84:732-747.
77. Burroughs AK, Matthews K, Qadiri M, et al. Desmopressin and bleeding time in patients with cirrhosis. Br Med J 1985;291:1377.
78. Mannucci PM, Vicente V, Vianello L, et al. Controlled trial of desmopressin (DDAVP) in liver cirrhosis and other conditions associated with a prolonged bleeding time. Blood 1986;67:1148-1153.
79. Schulman S, Hohnsson H. Heparin, DDAVP and the bleeding time. Thromb Haemost 1991;65:242-244.
80. Fremes SE, Wong BI, Lee E, et al. Meta-analysis of prophylactic drug treatment in the prevention of postoperative bleeding. Ann Thorac Surg 1994;58:1580.
81. Monroe DM, Hoffman M, Oliver JA, Roberts HR. A possible mechanism of action of F VII independent of tissue factor. Blood Coagul Fibrinolysis 1998;9:S15-S20.
82. Monroe DM, Hoffman M, Oliver JA, Roberts HR. Platelet activity of high dose factor VIIa is independent of tissue factor. Br J Haematol 1997;99:542-547.
83. Franchini M, Zaffanello M, Veneri D. Recombinant factor VIIa: an update on its clinical use. Thromb Haemostat 2005;93:1027-1035.
84. Park P, Fewel ME, Garton HJ, Thompson BG, Hoff JT. Recombinant activated factor VII for the rapid correction of coagulopathy in nonhemophilic coagulopathic patients. Neurosurgery 2003;53(1):34-38; discussion 38-39.
85. Gerlach R, Marquardt G, Wissing H, Scharrer I, Raabe A, Seifert V. Application of recombinant activated factor VII during surgery for a giant skull hemangiopericytoma to achieve safe hemostasis. J Neurosurg 2002;96:946-948.
86. Mayer SA, Brun NC, Begtrup K, et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2005;352(8):777-785.
87. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The Pharmacology and management of the vitamin K antagonists. In: 7th ACCP consensus conference on antithrombotic therapy. Chest 2004;126 (supplement):204S-233S.
88. Freeman WD, Brott TG, Barrett KM, et al. Recombinant factor VIIa for rapid reversal of warfarin anticoagulation in acute intracranial hemorrhage. Mayo Clin Proc 2004;79(12):1495-1500.
89. Lazio BE, Simard, JM. Anticoagulation in neurosurgical patients. Neurosurgery online 1999;45(4).
90. Mannucci PM, Remuzzi G, Pusineri F, et al. Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia. N Engl J Med 1983;308:8.
91. McFarmane RG. An enzyme cascade in the blood clotting mechanism and its function as a biological amplifier. Nature 1964;202;498-499.
92. Harrison P. The role of PFA-100 testing in the investigation and management of haemostatic defects in children and adults. Br J Haematol 2005;130:3-10.
93. Poon MC, d'Oiron R. Recombinant activated factor VII (NovoSeven) treatment of platelet-related bleeding disorders. International Registry on Recombinant Factor VIIa and Congenital Platelet Disorders Group. Blood Coagul Fibrinolysis 2000;11 (Suppl 1):S55-S68.